Three months after being denied takeover talks by AbbVie and rejected by Merck, Revolution Medicines has roared back.
On April 13, Revolution’s stock surged more than 40% shortly after market open, hitting an all-time high of $136.30 per share. In a single day, the biotech’s market value **swelled by approximately $7 billion**, reaching a total of $27.011 billion.
Investors were not betting blindly.
Based on top-line results from Revolution’s Phase 3 RASolute 302 trial, the oral pancreatic cancer drug daraxonrasib extended median overall survival (OS) to 13.2 months from 6.7 months with chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma patients, reducing the risk of death by 60%.
All primary and key secondary endpoints were met. Dr. Brian Wolpin, Professor at Harvard Medical School and lead investigator, called it “a major advance that will change clinical practice.” Jefferies analysts stated bluntly: “By any measure, these are best-in-class results.”
Subsequently, Oppenheimer raised Revolution’s price target from $150 to $165, and Leerink Partners from $115 to $147. According to TipRanks, the consensus rating is “Strong Buy”, with all 17 analysts issuing a Buy rating over the past three months.
By the close that day, Revolution’s stock had risen more than 70% year-to-date. Takeover rumors have resurfaced.
For Merck, which once sought to acquire Revolution, the situation has grown increasingly awkward. If the biotech’s earlier valuation surge was driven by MNC interest, Revolution has now proven with hard data that snubbing it may leave the giants unable to afford it — unless the buyer is willing to pay a staggering premium.
TONACEA
01
Overall Survival Doubled
Pancreatic cancer bears a fearsome nickname in oncology: “The King of Cancers.”
Among all major cancers, it has the lowest five-year survival rate at just 13%. Over 90% of pancreatic cancer cases are driven by RAS mutations, making RAS one of the most sought-after yet elusive targets in science for decades.
The RAS protein was once synonymous with “undruggable” in drug discovery. After more than 40 years of pursuit, the first crack in the target was opened in 2013 by Professor Kevan Shokat’s team at the University of California, San Francisco — Shokat is a key member of Revolution’s Scientific Advisory Board.
Revolution’s Phase 3 data released on April 13 validated the immense value of this technological approach.
In the RASolute 302 trial, patients receiving 300 mg once-daily oral daraxonrasib achieved a median OS of 13.2 months, compared to just 6.7 months with standard chemotherapy. Notably, the hazard ratio (HR) was 0.40, meaning daraxonrasib reduced the risk of death by 60% compared to chemotherapy.
The trial included not only patients with RAS G12 mutations but also the intention-to-treat (ITT) population with no detectable RAS mutations. Daraxonrasib demonstrated statistically significant and clinically meaningful benefit across all subgroups.
The drug’s mechanism of action is to inhibit activated RAS proteins, block their interaction with downstream signaling molecules, and thereby suppress tumor growth.
Lead investigator Wolpin stated clearly:
“Patients with metastatic pancreatic cancer desperately need new treatment options to extend survival. This study shows that daraxonrasib represents a meaningful step forward for patients who have failed prior therapy, and I believe it will change clinical practice.”
Revolution CEO Mark Goldsmith believes these results represent potential transformative progress, underscoring daraxonrasib’s potential to redefine the treatment landscape.
The market’s valuation correction was swift and fierce. Last month, Evaluate named daraxonrasib the most valuable orphan drug in biopharma R&D, forecasting $4 billion in sales by 2032. Mizuho analysts were even more aggressive, predicting peak global sales could reach $10 billion by 2035.
Revolution’s pipeline value extends far beyond daraxonrasib.
Public disclosures show the company is developing RMC-9805, a next-generation pan-KRAS inhibitor designed to target multiple KRAS variants including G12V and G13D, currently in active clinical development. In combination therapies, Revolution is exploring synergies between RAS inhibitors, immune checkpoint inhibitors, and SHP2 inhibitors.
It is this robust pipeline that gave Revolution the leverage to stand its ground against Merck in early-year acquisition talks.
TONACEA
02
The $10B+ Deal That Collapsed
The battle for Revolution heated up at the start of 2026.
On January 7, The Wall Street Journal first reported that AbbVie was in “advanced talks” with Revolution, valuing a potential deal at over $20 billion. Revolution’s stock immediately jumped ~28%, triggering multiple trading halts.
However, a dramatic reversal followed: AbbVie quickly issued a statement denying the talks, stating the company “was not engaged in any discussions with Revolution.”
As markets speculated over the true intent behind this confusion, the real suitor emerged.
According to the Financial Times, Merck emerged as the true bidder. Sources said the parties discussed an acquisition in the range of **$28–32 billion**. If completed, it would have been the largest pharmaceutical deal since Pfizer acquired Seagen for $43 billion in 2023.
Merck’s urgent pursuit of Revolution stemmed from a looming crisis: the Keytruda patent cliff.
In 2028, Merck’s “blockbuster drug” Keytruda will begin losing key market exclusivity. In 2025, the star drug generated over $30 billion in revenue, accounting for nearly half of Merck’s total revenue. When Keytruda’s patent protection expires, Merck will face a massive revenue gap in a short period.
Meanwhile, Merck’s acquisition strategy from 2025 to early 2026 shows a clear trajectory:
July 2025: Acquired Verona Pharma for ~$10 billion to enter the COPD space
November 2025: Bought Cidara Therapeutics for $9.2 billion to build a presence in influenza
March 2026: Purchased Terns Pharmaceuticals for $6.7 billion to expand into hematology
These moves laid the groundwork for a diversified post‑Keytruda portfolio — and Revolution was meant to be a critical piece. Yet the marriage collapsed over price disagreements.
Sources revealed that Merck and Revolution could never agree on valuation.
Although Revolution’s market cap was ~$16 billion in early January, Merck was negotiating with a company holding multiple late-stage pipeline assets and near-monopoly potential in pancreatic cancer.
Revolution knew its worth.
Its core asset daraxonrasib holds FDA Breakthrough Therapy Designation and Orphan Drug status. The company also owns an FDA Priority Review Voucher, which can shorten review time from 10–12 months to just a few months.
More importantly, early clinical data has shown striking synergy between Revolution’s RAS inhibitors and Merck’s Keytruda. Reports indicated elironrasib in combination with Keytruda achieved a 100% objective response rate (ORR) in PD‑L1‑high NSCLC patients.
This synergy gave Revolution irreplaceable strategic value to Merck, granting it uncompromising negotiating power.
In late January, the Wall Street Journal confirmed Merck ended potential takeover talks. At this year’s JPMorgan Conference, Merck CEO Robert Davis stated the company would focus on deals below $15 billion. With valuation disputes an unbridgeable gap, the pharmaceutical giant walked away.
TONACEA
03
The Newcomer’s Next Move
As Revolution’s stock hit a new all-time high on April 13, a lingering question resurfaced:
Will Merck come back? Or who will come knocking on Revolution’s door?
On paper, Revolution is now expensive.
Early January: ~$16 billion market cap
January 23: >$22 billion
April 13: >$27 billion
This far exceeds Merck’s self-imposed $15 billion deal limit and approaches the $28–32 billion range where talks collapsed in January.
But in the end, whether something is expensive is ultimately a relative question.
A March M&A wave ignited strong deal momentum across the biotech industry. In the last 12 days of March alone, seven deals over $1 billion closed, totaling **$29 billion**, including:
Merck’s acquisition of Terns for $6.7 billion
Eli Lilly’s purchase of Centessa for $7.8 billion
Biogen’s takeover of Apellis for $5.6 billion
Jefferies analysts predicted in their quarterly M&A review that the biotech M&A wave will continue throughout 2026.
For Revolution, daraxonrasib’s Phase 3 success eliminated major uncertainty.
Previously, two concerns weighed on the drug:
Early data released in January 2026 did not disclose specific progression-free survival (PFS) figures
Ongoing safety debates, with former Republican Senator Ben Sasse publicly citing side effects such as rash and bleeding
The Phase 3 readout — 60% mortality reduction, HR=0.40, manageable safety — is enough to bring any potential buyer back to the negotiating table.
So who is most likely to acquire Revolution?
The answer is still Merck — not because it is the wealthiest, but because it is the most desperate. The synergy between Revolution’s pipeline and Keytruda is nearly irreplaceable in the industry.
It now depends on whether Merck will pay a higher premium for its earlier decision to walk away. Jefferies analysts noted in an April 13 report that, based on conversations with investors, OS exceeding 12 months “should drive substantial upside,” and Revolution “delivered significantly above high expectations.”
Another name repeatedly mentioned is AbbVie.
AbbVie also faces a severe patent cliff. After losing exclusivity for its blockbuster immunology drug Humira, the company has made oncology a core growth pillar.
2024: Bought ADC company ImmunoGen for $10 billion
2025: Acquired in vivo CAR‑T therapy company Capstan Therapeutics for $2.1 billion
Notably, all 20 deals AbbVie completed in 2024 “focused entirely on early-stage opportunities,” a preference that aligns closely with Revolution’s pipeline profile. Yet AbbVie publicly denied takeover rumors in January, leaving near-term action uncertain.
Other potential bidders include Novartis and Pfizer, both facing pipeline pressure.
Novartis acquired Pikavation ($3 billion) and Excellergy ($2 billion) in March
Pfizer bought obesity drug developer Metsera for ~$10 billion in 2025
With patent cliffs counting down, big pharma’s appetite for high-quality assets has never been stronger.
Revolution holds a unique timeline: it plans to use its FDA Priority Review Voucher to accelerate its New Drug Application (NDA), cutting review time to months. In other words, daraxonrasib could gain approval by late 2026.
For any acquirer, buying a company on the verge of approval is vastly different from buying one still in clinical development with regulatory uncertainty. As approval nears, Revolution’s valuation premium will only grow.
The next act of this drama is just beginning.
Merck walked away thinking it had time to negotiate. The April 13 stock surge is a direct response to that hesitation.
Revolution is no longer a company Merck can “buy later.”
TONACEA
04
If Line: Turning East?
From Merck’s perspective, another possibility exists.
After missing out on Revolution, does Merck really have no other options?
Can it find a “high-quality, lower-cost” alternative to Revolution?
The answer may lie in Merck’s bullish strategy toward China.
Examples include:
August 2024: Acquired TopAlliance Biosciences’ CD3/CD19 bispecific CN201 (Phase 1) for up to $1.3 billion
November 2024: Licensed Lixin Pharma’s PD‑1/VEGF bispecific LM‑299 for $588 million upfront plus $2.7 billion in milestones
December 2024: Bought Hansoh Pharma’s oral small-molecule GLP‑1 receptor agonist HS‑10535 for ~$2 billion
Returning to the RAS sector:
Revolution has validated the synergy between RAS inhibitors and PD‑1 inhibitors.
Does China have RAS inhibitors that can fill this gap at a discounted valuation?
The truth is: yes, and more than one.
GenFleet Therapeutics GFH375
GFH375, an oral KRAS G12D inhibitor from GenFleet Therapeutics, is the world’s first KRAS G12D inhibitor in Phase 3 registration trials. Its Phase 3 study QILIN‑WING 01 for metastatic pancreatic cancer is underway at approximately 40 centers in China.
Recently, GFH375 was granted NMPA Breakthrough Therapy Designation (BTD) as monotherapy for patients with KRAS G12D‑mutant metastatic pancreatic cancer — its second BTD, following earlier recognition in NSCLC as the first domestic KRAS G12D inhibitor to receive BTD.
GenFleet’s U.S. partner Verastem Oncology initiated U.S. clinical trials for GFH375 in 2025, and the drug has been granted FDA Fast Track Designation for first‑ and later‑line KRAS G12D‑mutant pancreatic ductal adenocarcinoma.
If Revolution’s daraxonrasib represents the U.S. approach to RAS inhibition, GenFleet’s GFH375 offers a China alternative — at a far lower valuation than Revolution.
Jacobio Pharmaceuticals JAB‑23E73
Jacobio provides another option in the pan-KRAS inhibitor space.
In December 2025, Jacobio and AstraZeneca entered a global licensing agreement for the pan-KRAS inhibitor JAB‑23E73, with a total value of **$2.015 billion**, including $100 million upfront and up to $1.915 billion in milestones.
Of course, Chinese RAS assets are not without risk.
GFH375 remains in Phase 3, with a path to approval still ahead
JAB‑23E73 is in early clinical stages, with data maturity far below daraxonrasib
But China’s innovative drug advantage lies in speed and cost.
In the RAS sector, Chinese biotechs have demonstrated world-class development speed, with valuations generally far lower than their U.S. counterparts.
In this light, Merck’s gains and losses may be judged over a longer timeline.
参考资料：
This Biotech Stock Soars 39%. Pancreatic Cancer Trial Was a Success.
Revolution pancreatic cancer drug nearly doubles survival in key trial
Revolution Medicines data ‘a best-case outcome,’ says Jefferies
